Israel-based generics drug giant Teva Pharmaceutical Industries met analysts' forecasts, reporting fourth-quarter 2009 net profit of $379 million, or $0.42 per share, compared with a loss of $694 million or $0.88/share a year earlier. Annual non-GAAP net income and non-GAAP earnings per share were $3.0 billion and $3.37, up 22% and 11%, respectively, compared with the year ended 2008. Annual GAAP net income and EPS totaled $2.0 billion and $2.23, respectively, versus $609 million and $0.75 in 2008.
Net sales for the quarter increased 33% to $3.8 billion, compared to $2.85 billion in the fourth quarter of 2008. Net sales for the year increased 25% to $13.9 billion, compared to the previous year. The integration of US firm Barr Pharmaceutical's business - a $7.46 billion acquisition concluded in December 2008 - contributed to the growth in sales in all of Teva's geographies, particularly in the USA, Russia, Poland, Germany and Croatia.
Record global in-market sales were recorded for Copaxone (glatiramer) of $2.8 billion in the year ended 2009, up 25% in the fourth quarter and for the full year compared to 2008. The drug continues to be the leading multiple sclerosis (MS) therapy in the USA and globally, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze